Scarica l'app Stockscreener
74.59
0.87%
0.64
Pre-mercato:
74.20
-0.39
-0.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$73.95
Aprire:
$73.33
Volume 24 ore:
3.51M
Relative Volume:
0.74
Capitalizzazione di mercato:
$231.33B
Reddito:
$56.50B
Utile/perdita netta:
$8.30B
Rapporto P/E:
28.09
EPS:
2.655
Flusso di cassa netto:
$8.18B
1 W Prestazione:
+3.84%
1M Prestazione:
+7.40%
6M Prestazione:
+8.16%
1 anno Prestazione:
-8.83%
Intervallo 1D:
$73.22
$74.60
Intervallo di 1 settimana:
$72.57
$76.73
Portata 52W:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
74.59 | 229.28B | 56.50B | 8.30B | 8.18B | 2.655 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
AstraZeneca’s Phase II Study on AZD0901: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s Promising Study on AZD9829 for Blood Cancers: Key Insights for Investors - TipRanks
AstraZeneca’s Olaparib Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
AstraZeneca’s New Study on HER2 Expression in Gynecological Cancers: What Investors Need to Know - TipRanks
AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging - insights.citeline.com
AstraZeneca’s Latest Study on Asthma Inhalers: Key Insights for Investors - TipRanks
What are AstraZeneca PLC Depositary Receipt company’s key revenue driversMassive stock growth - jammulinksnews.com
How strong is AstraZeneca PLC Depositary Receipt company’s balance sheetGet timely advice on market trends - Jammu Links News
What is the risk reward ratio of investing in AstraZeneca PLC Depositary Receipt stockOutstanding yields - jammulinksnews.com
AstraZeneca’s AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension - The Globe and Mail
TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Proactive weekly health highlights: AstraZeneca, GSK, hVIVO, Avacta, and more - Proactive financial news
AstraZeneca’s Oral Drug Revolution: Could This Be the Future of Heart & Lung Treatments? - Smartkarma
AstraZeneca Can't Take Diabetes Drug IP Appeal To Top Court - Law360
AstraZeneca reports total voting rights of 1.55 billion ordinary shares - Investing.com
AstraZeneca’s New Study on Endometrial Cancer Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s AZD5004: A New Hope for Obesity and Overweight Management - TipRanks
AstraZeneca’s Ongoing Study on New Breast Cancer Treatment Shows Promise - TipRanks
AstraZeneca’s PRIMROSE Study: A New Frontier in Cancer Treatment - TipRanks
AstraZeneca’s New Heart Failure Study: Potential Market Impact - TipRanks
AstraZeneca’s Promising Study on Advanced Cancer Treatments: A Market Overview - TipRanks
AstraZeneca’s Ongoing Study on Olaparib: Potential Market Implications - The Globe and Mail
AstraZeneca’s LYNPARZA Study: Monitoring Safety in Breast Cancer Treatment - The Globe and Mail
AstraZeneca’s Calquence Study: Ensuring Safety in Real-World Use - The Globe and Mail
AstraZeneca’s New COPD Study: Potential Market Impact - The Globe and Mail
AstraZeneca’s Phase 3b Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Breast Cancer Treatment - The Globe and Mail
AstraZeneca’s Promising Phase III Study in Metastatic Breast Cancer: What Investors Need to Know - TipRanks
AstraZeneca’s Latest Phase IIIB Study: A Potential Game-Changer in Advanced Breast Cancer Treatment - TipRanks
AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Health - TipRanks
AstraZeneca’s Latest Study on AZD5004: Implications for Liver Impairment Treatment - TipRanks
AstraZeneca’s Tezepelumab Study: Real-World Impact on Asthma and Cough - TipRanks
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results? - Yahoo Finance
AstraZeneca Announces Updated Share Capital and Voting Rights - TipRanks
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - Yahoo Finance
AstraZeneca’s GEMINI-NSCLC Study: A New Era in Lung Cancer Research - TipRanks
AstraZeneca’s eVOLVE-Cervical Study: A New Hope for High-Risk Cervical Cancer - TipRanks
AstraZeneca’s PHRASE-HF Study: A Game Changer in Heart Failure Treatment? - TipRanks
AstraZeneca’s Innovative Propellant Study: Market Implications and Future Prospects - TipRanks
AstraZeneca’s COPD Study: New Propellant Shows Promise - TipRanks
AstraZeneca’s GEMINI-PeriOp GC Study: A New Horizon in Cancer Treatment - TipRanks
AstraZeneca PLC (NASDAQ:AZN) Q2 2025 Earnings Call Transcript - Insider Monkey
Why AstraZeneca Stock Was Topping the Market on Tuesday - MSN
AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab - MSN
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana - Yahoo.co
FIVE at FIVE: BAE, Taylor Wimpey, Arkle, Cornish Metal, AstraZeneca - Proactive financial news
AstraZeneca’s Asthma Study Completion: Market Implications and Insights - TipRanks
AstraZeneca’s New Study on Personalized Asthma Treatments in China: Market Implications - TipRanks
AstraZeneca’s Promising Phase IIb Study on AZD3427: Market Implications - TipRanks
AstraZeneca gets clean bill of health from leading investment bank - Proactive Investors
AstraZeneca Just Missed Estimates, but Here’s Why Bulls Aren’t Worried Yet - Yahoo Finance
Could Astrazeneca completely switch its allegiance to the US? - Yahoo.co
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):